Imaging Technology

SEPTEMBER 8, 2023

milla1cf Fri, 09/08/2023 - 16:25 September 8, 2023 — Positron Corporation , a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA. on September 18, 2023.

Clinic 95

Clinic Radiopharmaceuticals Medical Device IT 95

Imaging Technology

JULY 5, 2024

68Ga-DOTA-RM2 will be used as a companion diagnostic. While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate,” said Brian Markison, Lantheus CEO. For more information: www.lantheus.com Friday, July 5, 2024 - 06:00

Diagnostic 52

Diagnostic Radiopharmaceuticals Disease IT 52

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 75

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 75

Imaging Technology

JUNE 21, 2023

POSLUMA (formerly referred to as to as 18F-rhPSMA-7.3 ) is an optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075. Gauden , D.Phil.,

Diagnostic 75

Diagnostic Radiopharmaceuticals Imaging Medicare 75

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. Gauden , D.Phil.,

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93

AuntMinnie

MAY 30, 2023

Food and Drug Administration (FDA) has approved Blue Earth Diagnostics. Read more on AuntMinnie.com Related Reading: Blue Earth touts clinical results Blue Earth highlights results from PET tracer trial PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging Diagnostic Clinic 52

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

AuntMinnie

JUNE 20, 2024

F-18 fluorocholine (FCH) PET/CT could be a first-line technique over technetium-99m sestamibi (Tc-99m MIBI) SPECT/CT for imaging parathyroid tumors prior to surgery, according to a study published June 20 in JAMA Otolaryngology-Head & Neck Surgery. No complications occurred.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

Open Medscience

MAY 14, 2024

Positron Emission Tomography Imaging has advanced with cutting-edge technologies, enhancing diagnostic accuracy and expanding clinical applications dramatically. The post Breakthroughs in Positron Emission Tomography Imaging appeared first on Open MedScience.

Imaging 52

Imaging Diagnostic Clinic Nuclear Medicine 52

TTG Imaging Solutions

FEBRUARY 17, 2022

Imaging Conference & Expo: February 20 – 22, 2022 TTG Imaging Solutions will be exhibiting at the Imaging Conference & Expo in Napa, CA. Be sure to visit us at booth #304 Monday, February 21 and Tuesday, February 22 to discover solutions for equipment, nationwide service, parts, and clinical support.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

AuntMinnie

JUNE 27, 2023

Blue Earth Diagnostics, a Bracco company, is highlighting results from a stud. Read more on AuntMinnie.com Related Reading: FDA approves new PET tracer for prostate cancer imaging Blue Earth touts clinical results PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Clinic Imaging 52

Imaging Technology

OCTOBER 11, 2023

-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). SOFIE will continue its clinical development and commercialization program with [18F]FAPI-74 in the U.S. Financial terms were not disclosed. Sherly Mosessian , Ph.D,

Healthcare 93

Healthcare Healthcare Pharmaceutical Radiopharmaceuticals 93

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

MAY 14, 2024

milla1cf Tue, 05/14/2024 - 12:45 May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on their 40-year history of clinical and research collaboration. This alliance will help UH expand patient access and transform cancer care from discovery to recovery.

Hospital 103

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 103

AuntMinnie

FEBRUARY 12, 2024

Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. The clinical utility of amyloid PET scans has been systematically studied in many other countries.

PET Scan 99

PET Scan Disease Diagnose Radiopharmaceuticals 99

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

JANUARY 23, 2024

The machine will be used primarily for the manufacture of Strontium-82 for use in the diagnosis of cardiovascular disease, as well as for production of Germanium-68 for use in positron emission tomography (PET) imaging. To date, six Cyclone® 70 MeV machines and over 35 cyclotrons of 30 MeV have been installed worldwide.

Radiopharmaceuticals 96

Radiopharmaceuticals Disease Diagnostic Clinic 96

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”

Healthcare 80

Healthcare Healthcare Nuclear Medicine Computed Tomography 80

AuntMinnie

JUNE 14, 2024

Extravasations have never been required to be reported, NRC's senior health physicist Cindy Flannery said June 11 during a regulatory session at the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) recent meeting in Toronto. That might do away with diagnostic concerns, Flannery noted.

Nuclear Medicine 52

Nuclear Medicine Radiation Radiopharmaceuticals Medical 52

TTG Imaging Solutions

NOVEMBER 1, 2021

PITTSBURGH, PA (November 1, 2021) – TTG Imaging Solutions, LLC (TTG) announced today executive leadership changes that will drive the company’s next phase of growth following its 9th acquisition in 2 years of Medical Imaging Technologies, an Akron, Ohio based nuclear medicine equipment and service organization.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Medical Imaging 52

Imaging Technology

APRIL 2, 2024

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio.

Healthcare 95

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 95

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Chief Executive Officer of Blue Earth Diagnostics.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

NOVEMBER 2, 2023

2] In addition to the potential benefits of these AI models in clinical use, with roughly 5,000 immunotherapies in development today [3] , selecting patients more likely to respond could also help drug developers to speed up and increase the likelihood of success of clinical trials.

Pharmaceutical 59

Pharmaceutical Healthcare Healthcare Clinic 59

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

Nuclear Medicine 86

Nuclear Medicine Radiation Oncology Nursing Radiation 86

AuntMinnie

JANUARY 30, 2024

Efforts to bring quantitative MRI analysis into clinical practice received a boost with the availability of two new Category III Current Procedural Terminology (CPT) codes for brain MRI. Effective January 1, 2024, the new codes, 0865T and 0866T, support the use of software to analyze brain MRI exams with comparison to prior studies.

MRI 100

MRI Radiopharmaceuticals Disease Imaging 100

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. Our ongoing Phase 1/2 clinical trial ( NCT05413850 ) is evaluating 177Lu-rhPSMA-10.1

Radiopharmaceuticals 92

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 92

Imaging Technology

JULY 25, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 89

Radiopharmaceuticals Imaging Pharmaceutical Disease 89

Imaging Technology

JULY 11, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 70

Radiopharmaceuticals Imaging Pharmaceutical Disease 70

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 92

Diagnostic Radiopharmaceuticals Imaging Radiation 92

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 82

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 82

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 82

Medical Radiopharmaceuticals Pharmaceutical Radiation 82

AuntMinnie

JANUARY 19, 2024

The promise of imaging One challenge is that advances in Alzheimer’s care can only help people if they are reaching the right patients at the right time in their patient journey. More accurate diagnostic and monitoring tools can also help manage the high cost of new therapies by preventing the misuse of expensive treatments.

Disease 52

Disease Medicare Imaging PET Scan 52

AuntMinnie

OCTOBER 25, 2023

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, and PSI CRO, a global contract research organization, plan to conduct a trial using Clarity's phase III diagnostic trial of Clarify for prostate cancer patients.

Pharmaceutical 52

Pharmaceutical Radiopharmaceuticals Diagnostic Clinic 52